Briefcase

1-7 of 72 Activities
Title
Availability
Format
Credits
Launch Date
Buttons
Buttons
On-Demand
Briefcase
1
11/20/2026

Blueprint in Practice: The Inherited Regimen – Reassessing Long-Term Opioid Therapy Without Abandonment

This interactive CaseWise™ activity, one of four in the series, will bring these principles to life through realistic primary care decision-making. Through a patient case and structured clinical decision points, learners will apply physiologic and biopsychosocial assessment, validated pain assessment tools, multimodal treatment strategies, and CDC guideline recommendations to individualized care. Expert faculty will compare clinical approaches, clinical approaches and reinforce safe opioid prescribing, patient counseling on opioid safety and storage and disposal, assessment of risk for nonmedical opioid use, recognition of opioid use disorder (OUD) using DSM-5 criteria, and evidence-based, nonstigmatizing communication about diagnosis and treatment options.

1
11/20/2026
MM_FamMedHdsGrp25

Jill Schneiderhan, MD

MM_FamMedHdsGrp25

Jill Schneiderhan, MD

Christine Hunt, DO, MS

Christine Hunt, DO, MS

Buttons
On-Demand
Briefcase
1
02/27/2026

Transforming MS Care: Advanced Strategies in Multiple Sclerosis Management

In this CMEO BriefCase, expert faculty will walk learners through a real-world case, stopping for strategic discussions on the assessment of data on available anti-CD20 therapies to make appropriate recommendations for patients with MS, utilization of evidence-based guidelines for MS management to optimize treatment selection and monitor therapeutic outcomes, and the development of tailored MS treatment plans to address the unique physiological and social needs of older and pediatric patients.

1
02/27/2026

Mitzi Williams, MD, FAAN

Mitzi Williams, MD, FAAN

Tanuja Chitnis, MD

Tanuja Chitnis, MD

Buttons
On-Demand
Briefcase
0.5
01/30/2026

Personalizing Therapy in a Complex MuSK+ Patient

In the first activity of this CME Outfitters BriefCase series, expert faculty will differentiate MOAs, safety considerations, and efficacy data of currently approved FcRn antagonists for the treatment of gMG. Faculty will incorporate strategies to identify patients with gMG who may be appropriate candidates for FcRn antagonist therapy, and apply an individualized approach to treatment planning based on available evidence and patient preferences.

0.5
01/30/2026

Gil I. Wolfe, MD, FAAN

Gil I. Wolfe, MD, FAAN

Neelam Goyal, MD, FAAN

Neelam Goyal, MD, FAAN

Buttons
On-Demand
Briefcase
0.5
01/30/2026

Optimizing Dosing & Scheduling in a Partial Responder with gMG

Generalized myasthenia gravis (gMG) disrupts neuromuscular transmission, creating unpredictable symptom flare-ups and placing a significant burden on patients with this rare condition. Most commonly associated with antibodies targeting the acetylcholine receptor (AChR), and less commonly with muscle specific kinase (MuSK) or low-density lipoprotein receptor–related protein 4 (LRP4), gMG has forced patients and clinicians to navigate treatments that can be difficult to tolerate, slow to act, or limited by safety concerns. The expanding availability of neonatal Fc receptor (FcRn) blockers has introduced targeted options designed to reduce pathogenic IgG and improve symptoms. Clinicians, however, lack practical, evidence-based guidance on optimizing FcRn antagonist regimens in partial responders, including interval adjustments, transitions between cyclic and consistent dosing, structured monitoring, and safe steroid tapering, which results in persistent symptoms and avoidable treatment burden. Clinicians and multidisciplinary care teams require rigorous education in optimized dosing and longitudinal management to transform the care experience for patients with gMG.

In the second activity of this CME Outfitters BriefCase series, expert faculty will differentiate MOAs, safety, and efficacy profiles of currently approved FcRn antagonists for the treatment of gMG. Faculty will incorporate strategies to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists, and utilize an individualized approach to treatment planning for patients with gMG receiving FcRn antagonists based on the latest data as well as patient preferences.

0.5
01/30/2026

Gil I. Wolfe, MD, FAAN

Gil I. Wolfe, MD, FAAN

Neelam Goyal, MD, FAAN

Neelam Goyal, MD, FAAN

Buttons
On-Demand
Briefcase
1
12/19/2025

Revolutionizing Care: Innovative Approaches to Eosinophilic Esophagitis Treatment and Management

In this CME Outfitters BriefCase, expert faculty will identify how the complex, Th2-driven pathophysiology of EoE impacts diagnosis and treatment and integrate evidence-based treatments into the care of patients with EoE based on clinical trial data. Faculty will model development of long-term care plans for patients with EoE to address the chronic, progressive nature of this disease.

1
12/19/2025

Nirmala Gonsalves, MD, AGAF, FACG

Nirmala Gonsalves, MD, AGAF, FACG

Mirna Chehade, MD, MPH, AGAF, FAAAAI

Mirna Chehade, MD, MPH, AGAF, FAAAAI

Buttons
On-Demand
Briefcase
1
10/30/2025

Preventing the Preventable: Improving Mycophenolate Practices in Patients of Childbearing Potential

In this CME Outfitters BriefCase, expert faculty will utilize real-world case studies to explore gaps in clinician and patient adherence to the MREMS, including discussions and/or demonstrations of counseling, pregnancy testing, acceptable contraception methods, and monitoring of confirmed pregnancies via the Mycophenolate Pregnancy Registry to support ongoing pharmacovigilance.

1
10/30/2025

Jennifer Mylod, DNP

Jennifer Mylod, DNP

Silvi Shah, MD, MS, FAST, FASN, FNKF, FACP

Silvi Shah, MD, MS, FAST, FASN, FNKF, FACP